1. |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin, 2022, 72(1): 7-33.
|
2. |
Xu H, Zheng X, Ai J, et al. Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: A systematic review and meta-analysis of 13 110 patients. Int Immunopharmacol, 2023, 114: 109496. doi: 10.1016/j.intimp.2022.109496.
|
3. |
Greco L, Rubbino F, Dal Buono A, et al. Microsatellite instability and immune response: from microenvironment features to therapeutic actionability-lessons from colorectal cancer. Genes (Basel), 2023, 14(6): 1169. doi: 10.3390/genes14061169.
|
4. |
Yu HJ, Ren S , Xia JQ. Prognostic significance of the pretreatment pan-immune-inflammation value in cancer patients: an updated meta-analysis of 30 studies. Front Nutr, 2023, 10: 1259929. doi: 10.3389/fnut.2023.1259929.
|
5. |
Farag CM, Antar R, Akosman S, et al. What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types. Oncotarget, 2023, 14: 153-172.
|
6. |
Zhang L, Zhang Z, Guo H, et al. Systemic immune-inflammation index: A new indicator of predicting 1-, 2-and 3-year disease-free survival of patients with colon cancer. Adv Clin Exp Med, 2023, 32(1): 13-22.
|
7. |
Murata M. Inflammation and cancer. Environ Health Prev Med, 2018, 23(1): 50. doi: 10.1186/s12199-018-0740-1.
|
8. |
Proctor MJ, Morrison DS, Talwar D, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer, 2011, 47(17): 2633-2641.
|
9. |
Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 2002, 3(11): 991-998.
|
10. |
Chong X, Madeti Y, Cai J, et al. Recent developments in immunotherapy for gastrointestinal tract cancers. J Hematol Oncol, 2024, 17(1): 65. doi: 10.1186/s13045-024-01578-x.
|
11. |
Chen W, Xin S, Xu B. Value research of NLR, PLR, and RDW in prognostic assessment of patients with colorectal cancer. J Healthc Eng, 2022, 2022: 7971415. doi: 10.1155/2022/7971415.
|
12. |
Muangto T, Maireang K, Poomtavorn Y, et al. Study on preoperative neutrophil/lymphocyte (NLR) and platelet/lymphocyte ratio (PLR) as a predictive factor in endometrial cancer. Asian Pac J Cancer Prev, 2022, 23(10): 3317-3322.
|
13. |
Fang T, Wang Y, Yin X, et al. Diagnostic sensitivity of NLR and PLR in early diagnosis of gastric cancer. J Immunol Res, 2020, 2020: 9146042. doi: 10.1155/2020/9146042.
|
14. |
Wang D, Bai N, Hu X, et al. Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC. PeerJ, 2019, 7: e7132. doi: 10.7717/peerj.7132.
|
15. |
Fucà G, Guarini V, Antoniotti C, et al. The Pan-immune-inflammation value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. Br J Cancer, 2020, 123(3): 403-409.
|
16. |
Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammation value and prognosis in patients with esophageal cancer. Ann Surg Open, 2021, 3(1): e113. doi: 10.1097/AS9.0000000000000113.
|
17. |
Şahin AB, Cubukcu E, Ocak B, et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci Rep, 2021, 11(1): 14662. doi: 10.1038/s41598-021-94184-7.
|
18. |
Zhao H, Chen X, Zhang W, et al. Pan-immune-inflammation value is associated with the clinical stage of colorectal cancer. Front Surg, 2022, 9: 996844. doi: 10.3389/fsurg.2022.996844.
|
19. |
Yang XC, Liu H, Liu DC, et al. Prognostic value of pan-immune-inflammation value in colorectal cancer patients: A systematic review and meta-analysis. Front Oncol, 2022, 12: 1036890. doi: 10.3389/fonc.2022.1036890.
|
20. |
Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget, 2015, 6(38): 41370-41382.
|
21. |
Calderillo Ruiz G, Lopez Basave H, Vazquez Renteria RS, et al. The prognostic significance of HALP index for colon cancer patients in a Hispanic-based population. J Oncol, 2022, 2022: 4324635. doi: 10.1155/2022/4324635.
|
22. |
Sargin ZG, Dusunceli I. The effect of HALP score on the prognosis of gastric adenocarcinoma. J Coll Physicians Surg Pak, 2022, 32(9): 1154-1159.
|
23. |
Toshida K, Itoh S, Nakayama Y, et al. Preoperative HALP score is a prognostic factor for intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection: association with sarcopenia and immune microenvironment. Int J Clin Oncol, 2023, 28(8): 1082-1091.
|
24. |
Zhou J, Yang D. Prognostic significance of hemoglobin, albumin, lymphocyte and platelet (HALP) score in hepatocellular carcinoma. J Hepatocell Carcinoma, 2023, 10: 821-831.
|
25. |
Kurashina R, Ando K, Inoue M, et al. Platelet-to-lymphocyte ratio predicts the efficacy of pembrolizumab in patients with urothelial carcinoma. Anticancer Res, 2022, 42(2): 1131-1136.
|
26. |
Leetanaporn K, Hanprasertpong J. Predictive Value of the hemoglobin-albumin-lymphocyte- platelet (HALP) index on the oncological outcomes of locally advanced cervical cancer patients. Cancer Manag Res, 2022, 4: 1961-1972.
|
27. |
杨立民, 魁国菊. HALP与结肠癌临床病理特征的相关性及其对术后肝转移的预测价值. 中国普外基础与临床杂志, 2023, 30(8): 958-963.
|
28. |
Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res, 2007, 13(13): 3831-3839.
|
29. |
Akin Telli T, Bregni G, Vanhooren M, et al. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer. Cancer Treat Rev, 2022, 110: 102460. doi: 10.1016/j.ctrv.2022.102460.
|
30. |
Zhao N, Cao Y, Yang J, et al. Serum tumor markers combined with clinicopathological characteristics for predicting MMR and KRAS status in 2 279 Chinese colorectal cancer patients: A retrospective analysis. Front Oncol, 2021, 11: 582244. doi: 10.3389/fonc.2021.582244.
|